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Reply
We thank Dr. Pedersen and Ms. van den Broek for their inter-
est regarding our recent article (1) and for drawing attention to
the potential quality-of-life issues associated with implantable
cardioverter-defibrillator (ICD) shocks. The authors emphasize that
the relationship between ICD shocks, appropriate or inappropriate,
and health-related quality of life is neither simple nor linear. For
example, some studies have not found an effect of shocks on quality of
life. Other studies either have (2) or have not (3) found an effect
between number of shocks and adverse psychologic effect. Similarly,
patients with multiple appropriate shocks, for example, ventricular
arrhythmia storm, appear to be at particularly high risk for subsequent,
largely nonsudden, death in follow-up (4). Patient-related factors such
as age or personality type likely do play a role in the magnitude of
effect a shock has on the patient (1,5,6). In MADIT II (Multicenter
Automatic Defibrillator Trial II), while personality subtypes, such as
type D (7), were not specifically inventoried or analyzed ( 8), mental
health was not observed to change in patients completing follow-up
quality-of-life questionnaires, although declines in physical health
were noted for patients experiencing appropriate shocks, likely due to
worsening congestive heart failure (9). In summary, further work is
needed to reduce the occurrence of ICD shocks, both appropriate and
inappropriate, while maintaining the mortality reduction with ICDs,
and to anticipate, understand, and mitigate the effects of the shocks
when they cannot be prevented.
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Initial Assessment of
Clinical Impact of a Drug
Interaction Between Clopidogrel
and Proton Pump Inhibitors
After reading the article by Gilard et al. (1) regarding the influence of
omeprazole on the antiplatelet action of clopidogrel associated with
aspirin, we examined our medical and pharmacy databases for acute
myocardial infarction (MI) rates in members receiving clopidogrel
with or without concurrent proton pump inhibitor (PPI) therapy.
Our analysis included members younger than age 65 years who
were determined to be adherent to clopidogrel therapy. Members
were assigned to a no PPI exposure group (control), low PPI exposure
group, or high PPI exposure group based on adherence rates to PPIs.
Members were studied for a period of 1 year for claims with
International Classification of Diseases-9th Revision diagnoses indic-
ative of MI after starting clopidogrel therapy. We also examined
comorbidities and severity of illness at the time of first clopidogrel use.
Our findings revealed 1-year acute MI rates of 1.38% (66 of
4,800 patients) in the control group, 3.08% (22 of 712 patients) in
the low PPI exposure group, and 5.03% in the high PPI exposure
group. Using the control group MI incidence as the expected MI
rate, the difference in MI rates between the control and high
exposure groups was significant (p  0.05). Subsequent analysis
identified small but significant comorbidity differences between the
groups that could account for the findings. The high PPI exposure
group had a slightly greater number of individuals with pre-
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